ClinicalTrials.gg
CompletedNCT01502124Updated Feb 28, 2017

Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency

A Phase 3 interventional study of somatropin and somatropin in Growth Hormone Disorder and Growth Hormone Deficiency in Children, sponsored by Novo Nordisk A/S. Completed at 21 sites in United States. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-02-28.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 10 years 7 months after the study started (first participant enrolled May 2001, registered Dec 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
3 Years to 17 Years
Sex
All
01

Study summary

This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the safety profiles of Norditropin® (lyophilized somatropin) and Norditropin® cartridges (liquid somatropin) in children with growth hormone deficiency.

02

Conditions studied

  • Growth Hormone Disorder
  • Growth Hormone Deficiency in Children
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of short stature (height maximum 2 standard deviations of mean for age and gender) or inadequate growth deemed secondary to growth hormone deficiency (GHD)
  • Naïve to growth hormone therapy

Exclusion criteria

Exclusion Criteria:

  • Known or suspected allergy to the trial product or related products
  • Growth retardation attributable to causes other than GHD. Growth retardation attributable to diabetes mellitus, inborn errors of metabolism, primary bone disease, chromosomal disorders or disease of the genitourinary, cardiopulmonary, gastrointestinal or central nervous system; bone marrow transplantation or any syndrome known to give short stature (examples are: Prader-Willi Syndrome, Russell-Silver Syndrome, Turner Syndrome, Noonan Syndrome)
  • Intrauterine growth retardation: birth weight below 3rd percentile, adjusted for gestational age
  • Pregnancy or the intention to become pregnant
  • Breast-feeding
  • Administration of other growth-altering medication
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Active comparator
    Lyophilized

    Drug: somatropin

  • Experimental
    Liquid

    Drug: somatropin

Interventions

  • Injected subcutaneously 7 times per week after reconstitution with liquid buffer prior to use. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists

  • Injected subcutaneously 7 times per week. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists

06

What researchers measure

Primary outcomes

  1. Adverse events (especially injection site reactions)

  2. Serious adverse events

Secondary outcomes

  1. IGF-1 (Insulin-like growth factor 1) concentration

  2. IGFBP-3 (Insulin-like growth factor binding protein 3) concentration

07

Study locations

21 sites
  • Novo Nordisk Investigational Site
    Los Angeles, California 90027, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90048-1869, United States
  • Novo Nordisk Investigational Site
    Wilmington, Delaware 19899, United States
  • Novo Nordisk Investigational Site
    Washington, District of Columbia 20010, United States
  • Novo Nordisk Investigational Site
    Gainesville, Florida 32608, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33155, United States
  • Novo Nordisk Investigational Site
    Orlando, Florida 32806-1101, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33607, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30342, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60612, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60614, United States
  • Novo Nordisk Investigational Site
    Wichita, Kansas 67226, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40536-0284, United States
  • Novo Nordisk Investigational Site
    Louisville, Kentucky 40202, United States
  • Novo Nordisk Investigational Site
    Worcester, Massachusetts 01655, United States
  • Novo Nordisk Investigational Site
    Manhasset, New York 11030, United States
  • Novo Nordisk Investigational Site
    Akron, Ohio 44308-1062, United States
  • Novo Nordisk Investigational Site
    Hershey, Pennsylvania 17033, United States
  • Novo Nordisk Investigational Site
    Pittsburgh, Pennsylvania 15212, United States
  • Novo Nordisk Investigational Site
    Pittsburgh, Pennsylvania 15224, United States
  • Novo Nordisk Investigational Site
    Seattle, Washington 98105, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2001 to primary completion in Mar 2003, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2011
First posted
Dec 30, 2011
StartActual
May 8, 2001
Primary completionActual
Mar 5, 2003
CompletionActual
Mar 5, 2003
Last update
Feb 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01502124
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 30, 2011
Start date
May 8, 2001
Primary completion
Mar 5, 2003
Completion
Mar 5, 2003
Last update
Feb 28, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion